Company Overview
Boundless Bio, Inc., a clinical-stage oncology company, develops interrogating extrachromosomal DNA (ecDNA) directed therapies for treating patients with oncogene amplified cancers. Its lead product candidate is BBI-940, an ecDNA-directed therapeutic candidate (ecDTx) that is in Phase 1/2 clinical trial in patients with estrogen receptor positive and human epidermal growth factor receptor 2 negative breast cancer, as well as patients with triple-negative breast cancer luminal androgen receptor subtype. The company was formerly known as Pretzel Therapeutics, Inc. and changed its name to Boundless Bio, Inc. in July 2019. Boundless Bio, Inc. was incorporated in 2018 and is headquartered in San Diego, California.
Growth & Price Performance
Stock Price Performance
| 1 Year: | +144.44% |
| 6 Months: | +150.88% |
| 3 Months: | +100.00% |
| 1 Month: | -1.04% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)58.01 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | BOLD Boundless Bio, Inc. PHARMA | 2.86 | -1.00 | $65.06M | 0.00% | -43.97% | -67.86% | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Income | -12.09M | -13.96M | -14.95M | -16.88M | -19.39M | -18.71M | -17.34M | -17.06M | -15.15M | -14.47M | -24.38M |
| Net Income | -11.72M | -12.40M | -13.17M | -15.43M | -16.98M | -16.51M | -15.76M | -15.68M | -13.88M | -13.55M | -23.69M |
| Diluted EPS | -9.91 | -10.28 | -10.71 | -12.27 | -0.77 | -0.74 | -0.71 | -0.70 | -0.62 | -0.60 | -1.06 |
| R&D Expense | 9.50M | 11.07M | 11.64M | 13.13M | 14.73M | 14.09M | 12.14M | 12.22M | 10.67M | 9.73M | 13.97M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Operating Income | -54.80M | -73.27M | -63.55M |
| Net Income | -49.43M | -65.36M | -58.20M |
| Diluted EPS | -40.65 | -3.85 | -2.60 |
| R&D Expense | 42.64M | 55.27M | 44.84M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Total Assets | - | 129.89M | 206.41M | 157.06M |
| Total Equity | -81.70M | -127.08M | 150.64M | 98.65M |
| Cash & Equivalents | - | 23.71M | 26.59M | 17.87M |
| Total Liabilities | - | 9.36M | 55.77M | 58.41M |
| Current Liabilities | - | 9.36M | 8.13M | 12.54M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Operating Cash Flow | -46.85M | -60.84M | -46.66M |
| Investing Cash Flow | -38.26M | -26.10M | 37.80M |
| Financing Cash Flow | 97.90M | 89.82M | 141.00K |
| Capital Expenditure | -633.00K | -2.54M | -546.00K |
| Free Cash Flow | -47.49M | -63.38M | -47.21M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Gross Margin % | - | - | - |
| Operating Margin % | - | - | - |
| Net Margin % | - | - | - |
| ROE % | 38.9% | -43.4% | -59.0% |
| ROCE % | -45.5% | -37.0% | -44.0% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Arch Venture Management, Llc | 11.84% | 2.69M | $7.57M |
| 2 | FMR, LLC | 11.35% | 2.58M | $7.25M |
| 3 | Tang Capital Management, LLC | 11.25% | 2.56M | $7.19M |
| 4 | Adar1 Capital Management, LLC | 8.65% | 1.97M | $5.53M |
| 5 | Cormorant Asset Management, LP | 4.40% | 1.00M | $2.81M |
| 6 | Vanguard Capital Management LLC | 2.70% | 614.92K | $1.73M |
| 7 | Wellington Management Group, LLP | 2.45% | 556.23K | $1.56M |
| 8 | Millennium Management Llc | 2.10% | 478.64K | $1.34M |
| 9 | Renaissance Technologies, LLC | 2.07% | 471.57K | $1.33M |
| 10 | Alyeska Investment Group, L.p. | 1.32% | 300.00K | $843.00K |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for BOLD
Google Cloud Boss Makes Bold Claim About AI Chip Business - Investor's Business Daily
<a href="https://news.google.com/rss/articles/CBMijgFBVV95cUxNUnJjUklZVTZhTFRFY211R2YtWGxsSFN2THRNWHpCYTJWeFlXdjJiZVZ2d0hlUWdsbE9ENkpRTzVtU1NoVnRCU3ZsTDdDNlNFX3lrSkFvWWV6MGxIQ05KOHd5ZllRb0pkRGJ6VkU2aEpaOVhNOW8wZU1PeE9mejlCRFRUNUp2RmpzQ0s1ZV…
Bold prediction: by September 2027, the Lloyds share price will rise by… - Yahoo Finance UK
<a href="https://news.google.com/rss/articles/CBMijwFBVV95cUxNTHgtbzFiaV9pbkt5R1FmWUhKN0V4cFlzbWt4YkM0clg2R3Ztc2l3VVBSQVpDR2VvRFJoNVZwOVZwelhBNnBCMzB6SVhmejRzNEltd0hFVzdObVBuZjJ1ZlBCWVNmcWhHdGVfUTVzRUhxZnR4RzQ2V3VRcmxhTmp1TUoxd1FZa29pQ3ZrTj…
YUM Stock Retail Traders Turn Bullish After CEO Touts Pizza Hut Sale As ‘Big Bold Action’ - Stocktwits
<a href="https://news.google.com/rss/articles/CBMi5gFBVV95cUxNMzI4ZEwxRVBoZEIwd1RpZC0xUlkwd3FhYjAtaXA4OGxsSWVHQ1diNVYxY1ZyNEFUSERwU3RPY2RVUW13WVl5MFBLUHczckpHUTIxSFQxVl94aEVoS1RFLW44Q2tTTUNYRnlhLUNIa3Q5bERHbzN3ZmZLNHFGcnJ6U1RmZjk0dTVYWVlOUX…
Morgan Stanley delivers bold Carvana stock verdict - thestreet.com
<a href="https://news.google.com/rss/articles/CBMiogFBVV95cUxPZ0pfYjNnakVDUmJPeElQUG1pU3pvc3RJOXdOOXh2QW9tRzNBLVE2Rm9uSTB6QkUzeHQ5MkVTdUZ2dkdvRnZTbU1ZZVlDeFlnc0JibVhzcVFJNHZYOWNhVnFQcE94ekgyMmtFTE9VNmN2NEJ1dnJQVXpaOFNGZC1VMkhIM2xpX1ZCdU9fWD…
2,426,857 Boundless Bio (NASDAQ: BOLD) shares held by Zachary Hornby - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiwgFBVV95cUxNOXlJd3JMSE9zRTFuYWZaM21mN0FucGpDdmIyOG5WRUdMSVUzUjkyZjFJUWNLT2N3VjJSWk5lYmsweV9vVGhVRGhzSkIxX2xmZ3E5V0RrYmsxaFF5eG51VGRyTVh1ZWhPT3gyS25SalBtTkRMU0FkVUpGam1QUmxTWlc5LUxzUVdndUZ1Sz…
BOLD Stock Alert: Halper Sadeh LLC is Investigating Whether Boundless Bio, Inc. is Obtaining a Fair Price for its Shareholders - Business Wire
<a href="https://news.google.com/rss/articles/CBMijgJBVV95cUxNWWtBZnpRby00Rlc4NHZIR2puT0NSejEyUVFINWNjZkRZSzR3TXVEY3BzR2JGcTAzb0xZeDMwSWRIa1FjR01sdVRNNWhHaXpPeW5GSnRUQnA1dmNDUzFjTTlOeDY5d1F1VFVsNnNoeWt3M2FsaXVNd0xJcm5wM2s1VXgwNWJQaTZ3STJ2M2…
BOLD — Frequently Asked Questions
What is the current share price of Boundless Bio, Inc. (BOLD)?
As of 2026-09-19 21:16 PDT, Boundless Bio, Inc. (BOLD) trades at $2.86 on NasdaqGS. Its 52-week range is $1.05 to $3.00.
What is the market capitalisation of BOLD?
Boundless Bio, Inc. (BOLD) has a market capitalisation of $65.06M on NasdaqGS.
What is the P/E ratio of BOLD?
BOLD trades at a trailing price-to-earnings (P/E) ratio of -1.00. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 0.97.
What is the return on equity (ROE) of BOLD?
BOLD has a return on equity (ROE) of -67.86%. Its return on capital employed (ROCE) is -43.97%.
Is BOLD a good stock to buy?
This page provides a data-driven analysis of Boundless Bio, Inc. (BOLD), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.